Cargando…
Natural and vaccine-induced immunity are equivalent for the protection against SARS-CoV-2 infection
OBJECTIVES: To compare the long-term cumulative risk of SARS-CoV-2 infection associated with natural and vaccine-induced immunity. METHODS: Retrospective population-based cohort study based on registry of COVID-19 vaccinations and SARS-CoV-2 infections among 9.1 million citizens of Lombardy, Italy,...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10198735/ https://www.ncbi.nlm.nih.gov/pubmed/37267680 http://dx.doi.org/10.1016/j.jiph.2023.05.018 |
_version_ | 1785044798167580672 |
---|---|
author | Franchi, Matteo Pellegrini, Giacomo Cereda, Danilo Bortolan, Francesco Leoni, Olivia Pavesi, Giovanni Galli, Massimo Valenti, Giuseppina Corrao, Giovanni |
author_facet | Franchi, Matteo Pellegrini, Giacomo Cereda, Danilo Bortolan, Francesco Leoni, Olivia Pavesi, Giovanni Galli, Massimo Valenti, Giuseppina Corrao, Giovanni |
author_sort | Franchi, Matteo |
collection | PubMed |
description | OBJECTIVES: To compare the long-term cumulative risk of SARS-CoV-2 infection associated with natural and vaccine-induced immunity. METHODS: Retrospective population-based cohort study based on registry of COVID-19 vaccinations and SARS-CoV-2 infections among 9.1 million citizens of Lombardy, Italy, eligible for vaccination on 27th December 2020. Those who developed SARS-CoV-2 infection from 24th May to 14th September 2021, provided they did not yet receive the COVID-19 vaccine when infection was confirmed, and those who received the second mRNA vaccine dose, provided they had not yet developed the infection, were selected to be 1:1 matched for sex, age and index date. The latter corresponded to 90 days after confirmed infection or 14 days after vaccine administration. A control cohort including citizens who, on the index date, had neither developed infection nor received vaccination was also selected. Kaplan–Meier curves were used for comparing the cumulative incidence of new SARS-CoV-2 infection from the index date until 22nd June 2022. RESULTS: Overall, 19,418 1:1:1 risk-sets were included. After 9 months of follow-up, the cumulative risk of new SARS-CoV-2 infection was 21.8%, 22.0%, and 25.9%, respectively, among exposed to natural immunity, vaccine-induced immunity and unexposed. CONCLUSIONS: Equivalent potential for protecting against new SARS-CoV-2 infection was observed. |
format | Online Article Text |
id | pubmed-10198735 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101987352023-05-22 Natural and vaccine-induced immunity are equivalent for the protection against SARS-CoV-2 infection Franchi, Matteo Pellegrini, Giacomo Cereda, Danilo Bortolan, Francesco Leoni, Olivia Pavesi, Giovanni Galli, Massimo Valenti, Giuseppina Corrao, Giovanni J Infect Public Health Original Article OBJECTIVES: To compare the long-term cumulative risk of SARS-CoV-2 infection associated with natural and vaccine-induced immunity. METHODS: Retrospective population-based cohort study based on registry of COVID-19 vaccinations and SARS-CoV-2 infections among 9.1 million citizens of Lombardy, Italy, eligible for vaccination on 27th December 2020. Those who developed SARS-CoV-2 infection from 24th May to 14th September 2021, provided they did not yet receive the COVID-19 vaccine when infection was confirmed, and those who received the second mRNA vaccine dose, provided they had not yet developed the infection, were selected to be 1:1 matched for sex, age and index date. The latter corresponded to 90 days after confirmed infection or 14 days after vaccine administration. A control cohort including citizens who, on the index date, had neither developed infection nor received vaccination was also selected. Kaplan–Meier curves were used for comparing the cumulative incidence of new SARS-CoV-2 infection from the index date until 22nd June 2022. RESULTS: Overall, 19,418 1:1:1 risk-sets were included. After 9 months of follow-up, the cumulative risk of new SARS-CoV-2 infection was 21.8%, 22.0%, and 25.9%, respectively, among exposed to natural immunity, vaccine-induced immunity and unexposed. CONCLUSIONS: Equivalent potential for protecting against new SARS-CoV-2 infection was observed. The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. 2023-08 2023-05-20 /pmc/articles/PMC10198735/ /pubmed/37267680 http://dx.doi.org/10.1016/j.jiph.2023.05.018 Text en © 2023 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Original Article Franchi, Matteo Pellegrini, Giacomo Cereda, Danilo Bortolan, Francesco Leoni, Olivia Pavesi, Giovanni Galli, Massimo Valenti, Giuseppina Corrao, Giovanni Natural and vaccine-induced immunity are equivalent for the protection against SARS-CoV-2 infection |
title | Natural and vaccine-induced immunity are equivalent for the protection against SARS-CoV-2 infection |
title_full | Natural and vaccine-induced immunity are equivalent for the protection against SARS-CoV-2 infection |
title_fullStr | Natural and vaccine-induced immunity are equivalent for the protection against SARS-CoV-2 infection |
title_full_unstemmed | Natural and vaccine-induced immunity are equivalent for the protection against SARS-CoV-2 infection |
title_short | Natural and vaccine-induced immunity are equivalent for the protection against SARS-CoV-2 infection |
title_sort | natural and vaccine-induced immunity are equivalent for the protection against sars-cov-2 infection |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10198735/ https://www.ncbi.nlm.nih.gov/pubmed/37267680 http://dx.doi.org/10.1016/j.jiph.2023.05.018 |
work_keys_str_mv | AT franchimatteo naturalandvaccineinducedimmunityareequivalentfortheprotectionagainstsarscov2infection AT pellegrinigiacomo naturalandvaccineinducedimmunityareequivalentfortheprotectionagainstsarscov2infection AT ceredadanilo naturalandvaccineinducedimmunityareequivalentfortheprotectionagainstsarscov2infection AT bortolanfrancesco naturalandvaccineinducedimmunityareequivalentfortheprotectionagainstsarscov2infection AT leoniolivia naturalandvaccineinducedimmunityareequivalentfortheprotectionagainstsarscov2infection AT pavesigiovanni naturalandvaccineinducedimmunityareequivalentfortheprotectionagainstsarscov2infection AT gallimassimo naturalandvaccineinducedimmunityareequivalentfortheprotectionagainstsarscov2infection AT valentigiuseppina naturalandvaccineinducedimmunityareequivalentfortheprotectionagainstsarscov2infection AT corraogiovanni naturalandvaccineinducedimmunityareequivalentfortheprotectionagainstsarscov2infection |